FdaApplication
NDA 208215
Identifiers
- fda_app_no: NDA208215
Properties
| Property | Value |
|---|---|
| applicant_name | GILEAD SCIENCES INC |
| application_type | NDA |
| approval_date | 2016-04-04 |
Revenue by product
DESCOVY
| Period | Revenue |
|---|---|
| Q2 2026 | $967.0M* |
| Q1 2026 | $807.0M* |
| Q4 2025 | $819.0M* |
| Q3 2025 | $701.0M* |
| Q2 2025 | $653.0M* |
| Q1 2025 | $586.0M* |
| Q4 2024 | $617.0M* |
| Q3 2024 | $586.0M* |
| Q2 2024 | $485.0M* |
| Q1 2024 | $426.0M* |
| Q4 2023 | $510.0M* |
| Q3 2023 | $511.0M* |
| Q2 2023 | $516.0M* |
| Q1 2023 | $449.0M* |
| Q4 2022 | $537.0M* |
| Q3 2022 | $500.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| DESCOVY | EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | 200MG;EQ 25MG BASE | TABLET;ORAL |
| DESCOVY | EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | 120MG;EQ 15MG BASE | TABLET;ORAL |
2 products